株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint: クローン病-日本における医薬品の予測と市場分析

PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 298498
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint: クローン病-日本における医薬品の予測と市場分析 PharmaPoint: Crohn's Disease - Japan Drug Forecast and Market Analysis to 2022
出版日: 2014年01月31日 ページ情報: 英文 113 Pages
概要

クローン病(CD)市場は新たなバイオ医薬品の出現により、活発化しています。同市場において主流のTNF阻害剤の特許権保護が消失することで、HospiraのInflectraなど新たなバイオシミラーが台頭し、カナダや中国、インドなどの新興市場が同市場の成長にとって主要な役割を果たすと考えられます。日本では、特許の切れる2021年からバイオシミラーの市場浸透が始まると予測されています。

当レポートでは、日本におけるクローン病(CD)市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状
  • 予後
  • QOL

第4章 疾病の管理

  • 治療の概要
  • 日本
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
  • バイオシミラー

第6章 機会とアンメットニーズ

  • 概要
  • 個別化治療用バイオマーカーの要望
  • 抗TNF剤に反応しない患者のための医薬品
  • アンメットニーズのギャップ分析
  • 標的治療薬
  • 早期診断・治療の予測ツール

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • その他開発の後期段階にあるパイプライン製品

第8章 市場の見通し

  • 世界市場

第9章 日本

  • 予測
  • 主な出来事
  • 促進要因および阻害要因

第10章 付録

図表

目次
Product Code: GDHC210CFR

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

In contrast to the 7MM, but akin to Canada, Remicade will remain on patent in the Japanese CD market for a significant portion of the 10-year forecast period, with biosimilar erosion predicted from 2021 on. This, in turn, will lead to the brand experiencing year-on-year growth through to its peak-year sales in 2022.

Scope

  • Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Crohn's disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of drug performance.
  • Obtain sales forecast for drugs from 2012-2022 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. Japan
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Remicade (infliximab)
    • 5.3.2. Humira (adalimumab)
    • 5.3.3. Other Marketed Products
  • 5.4. Biosimilars
    • 5.4.1. Introduction
    • 5.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.4.3. Biosimilars in the Immunology Community
    • 5.4.4. By the Numbers: Biosimilars in Development
    • 5.4.5. The Impact of Biosimilars Will be Felt Through out the Pharmaceutical Industry

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach
  • 6.3. More Therapies for Anti-TNF-Refractory Patients
  • 6.4. Unmet Needs Gap Analysis
  • 6.5. Targeted Therapies
  • 6.6. Predictive Tools for Early Diagnosis and Treatment

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Entyvio (vedolizumab)
    • 7.2.2. Stelara (ustekinumab)
  • 7.3. Other Late-Stage Pipeline Products
    • 7.3.1. Cx601
    • 7.3.2. RHB-104 (clarithromycin + clofazimine + rifabutin)

8. Market Outlook

  • 8.1. Global Markets
    • 8.1.1. Drivers and Barriers - Global Issues

9. Japan

  • 9.1. Forecast
  • 9.2. Key Events
  • 9.3. Drivers and Barriers
    • 9.3.1. Driver: Pathways for biosimilar approval are already in place
    • 9.3.2. Driver: Increasing number of prevalent cases of CD
    • 9.3.3. Driver: Continued uptake of TNF inhibitors, particularly Remicade
    • 9.3.4. Driver: Launch of the first non-anti-TNF during the mid-forecast
    • 9.3.5. Driver: The well-developed universal healthcare system ensures insurance coverage for patients with chronic diseases
    • 9.3.6. Barrier: Biennial pricing system may limit long-term revenues for companies operating in this market
    • 9.3.7. Barrier: Time lag between drug approval and launch, due to the process required for listing a drug on the NHI
    • 9.3.8. Barrier: Regulatory approval is often contingent upon companies presenting domestic and/or Japanese-specific clinical trial data

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed CD Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline agents
  • 10.5. Physicians and Specialists Included in This Study
  • 10.6. Primary Research - Prescriber Survey
  • 10.7. About the Authors
    • 10.7.1. Author/Reviewer
    • 10.7.2. Global Head of Healthcare
  • 10.8. About GlobalData
  • 10.9. Disclaimer

List of Tables

  • Table 1: Symptoms of CD
  • Table 2: Treatment Guidelines for CD
  • Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013
  • Table 4: Leading Branded Drugs Used to Treat CD
  • Table 5: Product Profile - Remicade
  • Table 6: Remicade SWOT Analysis, 2013
  • Table 7: Product Profile - Humira
  • Table 8: Humira SWOT Analysis, 2013
  • Table 9: Summary of the Minor Therapeutic Classes in CD, 2013
  • Table 10: Biosimilars Pipeline, 2013
  • Table 11: Overall Unmet Needs in CD - Current Level of Attainment
  • Table 12: Clinical Unmet Needs in CD - Gap Analysis, 2013
  • Table 13: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013
  • Table 14: Comparison of Therapeutic Classes in Development for CD, 2013
  • Table 15: Product Profile - Entyvio
  • Table 16: Efficacy of Entyvio in GEMINI II Studies of CD
  • Table 17: Entyvio SWOT Analysis, 2013
  • Table 18: Product Profile - Stelara
  • Table 19: Comparison of Stelara's Phase IIb CERTIFI trial Efficacy Data Versus Tysabri's Phase III Efficacy Data in Anti-TNF Refractory CD Patients
  • Table 20: Stelara SWOT Analysis, 2013
  • Table 21: Product Profile - Cx601
  • Table 22: Cx601 SWOT Analysis, 2013
  • Table 23: Product Profile - RHB-104
  • Table 24: RHB-104 SWOT Analysis, 2013
  • Table 25: Global CD Market - Drivers and Barriers, 2012-2022
  • Table 26: Sales Forecasts ($) for CD in Japan, 2012-2022
  • Table 27: Key Events Impacting Sales for CD in Japan, 2012-2022
  • Table 28: CD Market in Japan - Drivers and Barriers, 2012-2022
  • Table 29: Key Launch Dates
  • Table 30: Key Patent Expiries
  • Table 31: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right)
  • Figure 2: Potential Biologic Drug Targets for CD
  • Figure 3: Patient Care Path for CD
  • Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022
  • Figure 5: Sales for CD in Japan by Drug Class, 2012-2022
Back to Top